Lin Yao

Lin Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lin Yao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of Novel Non-Oxime Reactivators Showing In Vivo Antidotal Efficiency for Sarin Poisoned Mice

    by Zhao Wei, Xinlei Zhang, Huifang Nie, Lin Yao, Yanqin Liu, Zhibing Zheng, Qin Ouyang

    A family of novel efficient non-oxime compounds exhibited promising reactivation efficacy for VX and sarin inhibited human acetylcholinesterase was discovered. It was found that aromatic groups coupled to Mannich phenols and the introduction of imidazole to the ortho position of phenols would dramatically enhance reactivation efficiency. Moreover, the in vivo experiment was conducted, and the results demonstrated that Mannich phenol L10R1 (30 mg/kg, ip) could afford 100% 48 h survival for mice of 2*LD50 sarin exposure, which is promising for the development of non-oxime reactivators with central efficiency.


  • Chiral Ferrocenyl N,N Ligands with Intramolecular Hydrogen Bonds for Highly Enantioselective Allylic Alkylations

    by Lin Yao, Huifang Nie, Dongxu Zhang, Libin Wang, Yuhao Zhang, Weiping Chen, Zhenhua Li, Xueying Liu, Shengyong Zhang

    Several new ferrocene‐derived bidentate N ligands, which contain multiple chiral factors, have been designed and synthesized by a rational combination of oxazoline and pyridine. Their catalytic performances were investigated preliminarily in Pd‐catalyzed asymmetric allylic alkylation, and excellent reactivities and enantioselectivities (up to 99 % yield and 98 % ee) were realized if we used the ligand with a matched chirality. DFT calculations were used to illustrate that an intramolecular hydrogen bond formed between the hydroxyl group and the oxazoline fragment of the ligand contributed to the optimal conformation of the ligand‐Pd‐allyl complex.